Meomics
Advancing Neuro-Active Medication with Data-Driven Insights
MeOmics, a Welsh biotech startup, has developed a revolutionary method for performing in-silico testing of neuro-active medication. Their approach aims to personalise treatment for neurological conditions by analysing how brain neurons react to specific medications in the laboratory using non-invasive tissue samples. This opens up new possibilities for treating neurological patients by focusing on brain cells and addressing unique needs.
What Did We Do?
CEMET partnered with MeOmics to tackle a crucial part of this technology: interpreting the complex neurological data generated from these tests. The goal was to determine how brain neuron samples react to medications and assess the health of the cells. Since this type of data had never been analysed in such a context before, the challenge was to delve into completely new scientific territory.
How Did We Do It?
The CEMET team worked to develop advanced methods for processing and interpreting the intricate neurological data produced by MeOmics' in-silico tests. By creating new models and algorithms, they were able to translate raw neuron activity into valuable insights regarding cell health and drug efficacy. This involved carefully examining neuron behaviour to uncover patterns that could predict how patients would respond to neuro-active medications.
The collaboration between CEMET and MeOmics was essential in solving the challenges posed by this groundbreaking research. By working closely together, they succeeded in building a framework to better understand neuron activity in relation to drug testing, pushing forward the science behind personalised neurological treatments. This project illustrates CEMET's expertise in supporting innovative solutions, expanding the potential for personalised medicine, and providing new treatment options for previously underserved patient groups.
CEMET is proud to continue to support MeOmics through further development. To find out more about their latest work visit their website or follow them on LinkedIn and Twitter.
This project is jointly funded by the UK Government’s Shared Prosperity Fund and Cardiff Capital Region (CCR) the Academic-Industry Partnerships programme, part of the Cluster Development and Growth Programme.
